Anti-beta Amyloid 1-42 antibody [mOC64] - Low endotoxin, Azide free (ab224275)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [mOC64] to beta Amyloid 1-42 - Low endotoxin, Azide free
- Suitable for: Dot blot, IHC-P, IHC-FrFl
- Reacts with: Mouse, Human
Overview
-
Product name
Anti-beta Amyloid 1-42 antibody [mOC64] - Low endotoxin, Azide free
See all beta Amyloid 1-42 primary antibodies -
Description
Rabbit monoclonal [mOC64] to beta Amyloid 1-42 - Low endotoxin, Azide free -
Host species
Rabbit -
Tested applications
Suitable for: Dot blot, IHC-P, IHC-FrFlmore details -
Species reactivity
Reacts with: Mouse, Human -
Immunogen
Other Immunogen Type. Amyloid beta 1-42 fibrils were used as the immunogen.
Database link: P05067 -
Positive control
- beta Amyloid (Aß) 1-42. IHC-P: FFPE Human Brain Alzheimer.
-
General notes
ab224275 is the Low endotoxin, azide-free version of ab201060 This format is designed for in vitro and in vivo studies, including neutralization, blocking or activation/proliferation.
Our Low endotoxin, azide-free formats have low endotoxin level (≤ 1 EU/ml, determined by the LAL assay) and are free from azide, to achieve consistent experimental results in functional assays.
This antibody was developed as part of a collaboration between Abcam and Professor Charles Glabe, UC Irvine.
ab224275 recognizes a conformation-dependent, aggregation-selective epitope of beta amyloid. mOC64 immunoreactivity maps to residues 3-6 (EFRH) of Aß, and preferentially binds to SDS-resistant oligomers over monomer on Western blots (Hatami et al. 2014). The epitope is insensitive to thermal denaturation (Hatami et al. 2014). It does not recognize pyproglytaminylated Aß at position 3 (Aß3(pE)–42) (Nussbaum et al. 2012).
For further information on the immunogen, please refer to Hatami et al. 2014 and Kayed et al. 2007.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Reproducibility is key to advancing scientific discovery and accelerating scientists’ next breakthrough.
Abcam is leading the way with our range of recombinant antibodies, knockout-validated antibodies and knockout cell lines, all of which support improved reproducibility.
We are also planning to innovate the way in which we present recommended applications and species on our product datasheets, so that only applications & species that have been tested in our own labs, our suppliers or by selected trusted collaborators are covered by our Abpromise™ guarantee.
In preparation for this, we have started to update the applications & species that this product is Abpromise guaranteed for.
We are also updating the applications & species that this product has been “predicted to work with,” however this information is not covered by our Abpromise guarantee.
Applications & species from publications and Abreviews that have not been tested in our own labs or in those of our suppliers are not covered by the Abpromise guarantee.
Please check that this product meets your needs before purchasing. If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, as well as customer reviews and Q&As.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C. Do Not Freeze. -
Storage buffer
pH: 7.2
Constituent: PBS -
Carrier free
Yes -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
mOC64 -
Isotype
IgG -
Research areas
Images
-
IHC image of beta Amyloid 1-42 staining in Human Brain Alzheimer formalin fixed paraffin embedded tissue section*, performed on a Leica Bond™ system using the standard protocol F. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH6, epitope retrieval solution 1) for 20 mins. The section was then incubated with ab201060, 1µg/ml, for 15 mins at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.
For other IHC staining systems (automated and non-automated) customers should optimize variable parameters such as antigen retrieval conditions, primary antibody concentration and antibody incubation times.
*Tissue obtained from the Human Research Tissue Bank, supported by the NIHR Cambridge Biomedical Research Centre
This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab201060).
-
Dot blot analysis of beta Amyloid 1-42 labeled with ab201060 at 1/7000 dilution.
Lane 1: beta Amyloid (Aβ) 1-40.
Lane 2: beta Amyloid (Aβ) 1-42.
Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated (ab97051) at 1/5000 dilution was used as secondary antibody.
Blocking and diluting buffer: 5% NFDM/TBST.
Exposure time: 30 seconds.Antibody reactivity was assessed using a dot blot, which is a non-quantitative method that maintains the native conformation of beta Amyloid. Beta Amyloid 1-40 and 1-42 peptides underwent the following aggregation conditions before being spotted onto a nitrocellulose membrane and detected using ab201060:
Monomers: 0.3 mg of beta Amyloid peptide was dissolved in 30 µl 100 mM NaOH and incubated at room temperature for 10 minutes. It was then diluted with 970 µl of 1% SDS and boiled for five minutes.
Oligomers: 0.3 mg of beta Amyloid peptide was dissolved in 30 µl 100 mM NaOH and incubated at room temperature for 10 minutes. It was then diluted with 970 µl of 10 mM phosphate buffer pH 7.4 containing 0.02% sodium azide and incubated at room temperature for four days.
Fibrils: 0.3 mg of beta Amyloid peptide was dissolved in 1 ml 50% hexafluoroisopropanol (HFIP) with 0.02% sodium azide. It was then stirred constantly for nine days; the first seven with a cap on and the final two with the cap removed to allow evaporation of the HFIP. Fibrils were then sedimented at 20,000 rpm in a microcentrifuge for 20 minutes and resuspended in 1 ml of PBS + 0.02% sodium azide.This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab201060).
-
Negative control (secondary ab only):
Lane 1: beta Amyloid (Aβ) 1-40.
Lane 2: beta Amyloid (Aβ) 1-42.
Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated (ab97051) at 1/5000 dilution was used as secondary antibody.
Blocking and diluting buffer: 5% NFDM/TBST.
Exposure time: 30 seconds.This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab201060).
-